A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

Exclusion Criteria

• •History of any clinically important disease or disorder.
• •History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• •Any clinically important abnormalities in hematology, clinical chemistry, urinalysis, coagulation results or other laboratory values and vital signs.
• •Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus (HIV).
• •Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram (ECG) at Screening.
• •Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
• •Current smokers or those who have smoked or used nicotine products within the previous 3 months prior to screening.
• •Positive screen for drugs of abuse, or alcohol or cotinine at Screening.
• •History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity.
• •History of hypersensitivity to dipeptidyl peptidase 4 (DPP4) inhibitors.